324 filings
Page 3 of 17
8-K
pjil8noe
17 Feb 22
PolarityTE Announces Allowance of Fourth U.S. Patent
8:00am
8-K
gpmijco891jmm0qs6b8
11 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
m7mw0gc
18 Jan 22
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
8:00am
8-K
rjo09j5 t4az2pac
23 Dec 21
Departure of Directors or Certain Officers
4:30pm
8-K
wms1wdu8w8l
20 Dec 21
PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
8:00am
8-K
14k2e2u7ee7hjof
17 Dec 21
Entry into a Material Definitive Agreement
5:00pm
8-K
vdh5uum8odqji267 5op
10 Nov 21
PolarityTE Reports Third Quarter Financial Results and Provides Business Update
7:00am
8-K
e3dcma1g6f yldjurur
7 Oct 21
PolarityTE Provides Update on Investigational New Drug Application
8:00am
8-K
m10g0 aoyp4j3ouer
1 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
kwd e9dsnu3
9 Sep 21
Regulation FD Disclosure
8:01am
8-K
kkod7 8dut0fbq7k7
2 Sep 21
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg
8:00am
8-K
m3dmv47qgxb3q9qh78
27 Aug 21
Departure of Directors or Certain Officers
12:00am
8-K
buxzzlk59yfn
24 Aug 21
Departure of Directors or Certain Officers
8:00am
8-K
otnkwopu
16 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
1p7ulav9iqg53
12 Aug 21
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
4:00pm
8-K
rxxvk nhanb
28 Jul 21
Regulation FD Disclosure
8:00am
8-K
x014h ehr
26 Jul 21
Other Events
8:00am
8-K
vn0q3pdskohgyq e2l
12 Jul 21
PolarityTE Receives Notice of Allowance for Chinese Patent
8:00am
8-K
eg54mw gx
17 Jun 21
Termination of a Material Definitive Agreement
4:45pm
8-K
p76fjs25ciexn4np
13 May 21
PolarityTE Reports First Quarter Results and Provides Business Update
4:26pm